Zongertinib Plus Fulvestrant for HER2-Mutated Breast Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (zongertinib and fulvestrant) for advanced breast cancer that is hormone-receptor positive but has a specific HER2 mutation. The trial aims to see if this combination can help patients whose cancer has progressed despite previous hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (unresectable or metastatic) breast cancer confirmed by imaging
- Your cancer is hormone-receptor positive and HER2-negative with a known HER2 mutation
- Your cancer has progressed after at least one prior hormone therapy (with or without CDK4/6 inhibitor)
- You have not received more than two chemotherapy regimens for advanced disease
- You have not previously received HER2-directed tyrosine kinase inhibitors (but other HER2 treatments like T-DXd are allowed)
- You are able to swallow pills and have no significant stomach or bowel problems that would prevent absorption
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
This trial tests an experimental drug (zongertinib) for people with advanced solid tumors that have certain changes in the HER2 gene. It's for those who have already tried at least one standard treatment and need more options.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
This trial tests a new drug, NTQ1062, combined with fulvestrant in people with a type of breast cancer called HR-positive, HER2-negative that has spread or come back. The study aims to see if this combination helps shrink or control the cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.